IGC Pharma, Inc. (NASDAQ:IGC)

PRESS RELEASE

published on 11/14/2024 at 14:30, 1 year 6 months ago

IGC Pharma Reports Second Quarter Fiscal 2025 Results, Showcasing Progress in Its Alzheimer’s Pipeline
IGC Pharma, Inc. announces Q2 FY2025 financial results and strategic advancements including breakthroughs in Alzheimer's treatment pipeline. Revenue grows 42% to $412k. R&D expenses decrease 28%

Financial Results R&D Expenses Q2 FY2025 IGC Pharma Alzheimer's Treatment
BRIEF

published on 11/06/2024 at 14:35, 1 year 6 months ago

IGC Pharma met en avant des avancées stratégiques dans les thérapies contre la maladie d'Alzheimer et la perte de poids

Intelligence Artificielle Perte De Poids Agonistes Du GLP-1 IGC Pharma Traitement De La Maladie D'Alzheimer
BRIEF

published on 11/06/2024 at 14:35, 1 year 6 months ago

IGC Pharma Highlights Strategic Advances in Alzheimer's and Weight Loss Therapies

Weight Loss Artificial Intelligence GLP-1 Agonists IGC Pharma Alzheimer's Treatment
PRESS RELEASE

published on 11/06/2024 at 14:30, 1 year 6 months ago

IGC Pharma Announces Publication of IMS Spotlight Interview Highlighting Strategic Expansion in Alzheimer’s and Weight Loss Therapies
IGC Pharma, Inc. (NYSE American: IGC) announces a new interview with CEO Ram Mukunda discussing strategic expansion into metabolic and neurological markets, focusing on Alzheimer's and weight loss therapies, leveraging AI for diverse pipeline

Interview Neurodegenerative Disorders Metabolic Disorders IGC Pharma Ram Mukunda
BRIEF

published on 10/17/2024 at 14:35, 1 year 7 months ago

IGC Pharma étend son essai sur la maladie d'Alzheimer au Canada grâce à un partenariat avec Baycrest

IGC Pharma IGC-AD1 Essai Sur La Maladie D'Alzheimer Partenariat Baycrest Phase 2 Clinique
BRIEF

published on 10/17/2024 at 14:35, 1 year 7 months ago

IGC Pharma Expands Alzheimer's Trial to Canada with Baycrest Partnership

IGC Pharma Alzheimer's Trial IGC-AD1 Baycrest Partnership Phase 2 Clinical
PRESS RELEASE

published on 10/17/2024 at 14:30, 1 year 7 months ago

IGC Pharma Announces Patient Enrollment at Toronto's Baycrest in Phase 2 Trial Investigating IGC-AD1
IGC Pharma expands Phase 2 trial to Canada at Baycrest Academy for Research and Education in Toronto, Ontario, to investigate IGC-AD1 for treating agitation in Alzheimer's dementia

Phase 2 Trial Alzheimer's IGC Pharma Agitation Treatment Baycrest Academy
BRIEF

published on 10/03/2024 at 15:05, 1 year 7 months ago

IGC Pharma Secures Two Awards in NIH's AI PREPARE Challenge

AI Technology Healthcare Innovation IGC Pharma Alzheimer's Prediction NIH Challenge
BRIEF

published on 10/03/2024 at 15:05, 1 year 7 months ago

IGC Pharma remporte deux prix lors du concours AI PREPARE Challenge du NIH

Technologie De L'IA Innovation Dans Le Domaine De La Santé IGC Pharma Prédiction De La Maladie D'Alzheimer Défi Du NIH
PRESS RELEASE

published on 10/03/2024 at 15:00, 1 year 7 months ago

IGC Pharma Wins 2 Prizes in Phase 1 of National Institutes of Health's AI PREPARE Challenge
IGC Pharma, Inc. wins 2 awards in the PREPARE Challenge for Alzheimer's research with its MHAS entry. Recognition highlights leadership in AI for disease prediction

Artificial Intelligence Healthcare Innovation Alzheimer's Research IGC Pharma PREPARE Challenge

Published on 05/22/2026 at 00:45, 1 hour 48 minutes ago

Credissential Announces Private Placement
Published on 05/21/2026 at 23:00, 3 hours 33 minutes ago

Silver Wolf Adopts Semi-Annual Financial Reporting
Published on 05/21/2026 at 23:00, 3 hours 33 minutes ago

Medicure Reports Financial Results for Quarter Ended March 31, 2026 and Schedules May 25, 2026 Conference Call
Published on 05/21/2026 at 23:00, 3 hours 33 minutes ago

Revival Gold Announces Adoption of Shareholder Rights Plan and Corporate Update
Published on 05/21/2026 at 22:15, 4 hours 18 minutes ago

Linear Announces Acquisition, Share Consolidation and Private Placement

View all ACCESSWIRE

Published on 05/21/2026 at 21:45, 4 hours 48 minutes ago

Rendeavour becomes the African Continental Free Trade Area's inaugural implementation partner for African industrialisation and trade infrastructure
Published on 05/21/2026 at 20:10, 6 hours 23 minutes ago

Ernst Russ AG Divests MV 'EF Emira' and Raises Full-Year 2026 Guidance
Published on 05/21/2026 at 20:05, 6 hours 27 minutes ago

EQS-Adhoc: Ernst Russ AG: Upward revision of the guidance for the financial year 2026
Published on 05/21/2026 at 20:00, 6 hours 33 minutes ago

VINFAST INTRODUCES THE NEW-GENERATION VF 8, FEATURING COMPREHENSIVE ENHANCEMENTS
Published on 05/21/2026 at 18:26, 8 hours 6 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares

View all EQS

Published on 05/21/2026 at 17:50, 8 hours 43 minutes ago

CDA - H1 results 2025 2026
Published on 05/21/2026 at 17:45, 8 hours 48 minutes ago

CEGEDIM: DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS
Published on 05/21/2026 at 17:45, 8 hours 48 minutes ago

CEGEDIM: DECLARATION D’ACTIONS ET DE DROITS DE VOTE
Published on 05/21/2026 at 17:45, 8 hours 48 minutes ago

CDA - Résultats de 1er semestre 2025 2026
Published on 05/21/2026 at 16:35, 9 hours 58 minutes ago

260521 BENETEAU Déclaration du nombre d'actions et de droits de vote au 30-04-2026

View all LES ECHOS COMFI WIRE

News